Full Press Release Details
| Dr. Reddy s Laboratories Ltd. | ||||
| 8-2-337, Road No. 3, Banjara Hills, | ||||
| Hyderabad - 500 034, Telangana, | ||||
| India. | ||||
| CIN: L85195TG1984PLC004507 | ||||
| Tel: +91 40 4900 2900 | ||||
| Fax: +91 40 4900 2999 | ||||
| Email: mail@drreddys.com | ||||
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | Exchange Plaza | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai 400 001 | Mumbai 400 051 | |
| Fax Nos.: 022-22723121/22723719/ | Fax Nos.: 022-26598120/26598237/ | |
| 22722037/22722039 | 26598238 |
Arzneimittel GmbH, Germany (our wholly-owned subsidiary) received a communication from the Regulatory Authority of Germany (Regierung von Oberbayern) last night, that the GMP compliance certificate in respect of the Company s Formulations
Manufacturing Unit 2 plant in Bachupally, Hyderabad is not renewed consequent to the recent inspection of the plant. Pending revocation of the non-compliance notification, the plant will not be able to make any further despatch to the European Union
until the next inspection, to be initiated by an invitation from betapharm.
This is for your information and record.
CC:- New York Stock Exchange Inc. (Stock Code: RDY)